Determination of combretastatin A-4 and its phosphate ester prodrug in plasma by high-performance liquid chromatography

被引:23
作者
Stratford, MRL [1 ]
Dennis, MF [1 ]
机构
[1] Mt Vernon Hosp, Canc Res Trust, Gray Lab, Northwood HA6 2JR, Middx, England
来源
JOURNAL OF CHROMATOGRAPHY B | 1999年 / 721卷 / 01期
关键词
combretastatin A-4;
D O I
10.1016/S0378-4347(98)00458-7
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
High-performance liquid chromatography with both absorbance and fluorescence detection has been applied to the determination of the potential anti-tumour agent combretastatin A-4 and its phosphate ester in murine and human plasma. The presence of different interfering peaks in the two species makes absorbance detection at 295 nm the method of choice for the mouse, and fluorescence detection (295 nm/390 nm) for human plasma. The calibration was linear over the range studied (0.01-50 mu M for combretastatin A-4, 0.02-200 mu M for combretastatin A-4 phosphate), with quantitation limits of 0.05 mu M for both drugs in the mouse, and 0.05 mu M and 0.0125 mu M for the phosphate ester and free drug, respectively, in human plasma. The method should be useful for pharmacokinetic studies in the forthcoming Phase I clinical trial of combretastatin A-4 phosphate. (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:77 / 85
页数:9
相关论文
共 8 条
[1]   Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status [J].
Beauregard, DA ;
Thelwall, PE ;
Chaplin, DJ ;
Hill, SA ;
Adams, GE ;
Brindle, KM .
BRITISH JOURNAL OF CANCER, 1998, 77 (11) :1761-1767
[2]   PHASE-I EVALUATION OF A WATER-SOLUBLE ETOPOSIDE PRODRUG, ETOPOSIDE PHOSPHATE, GIVEN AS A 5-MINUTE INFUSION ON DAY-1, DAY-3, AND DAY-5 IN PATIENTS WITH SOLID TUMORS [J].
BUDMAN, DR ;
IGWEMEZIE, LN ;
KAUL, S ;
BEHR, J ;
LICHTMAN, S ;
SCHULMAN, P ;
VINCIGUERRA, V ;
ALLEN, SL ;
KOLITZ, J ;
HOCK, K ;
ONEILL, K ;
SCHACTER, L ;
BARBHAIYA, RH .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (09) :1902-1909
[3]  
CHAPLIN DJ, 1996, J CANC, V74, pS86
[4]  
Dark GG, 1997, CANCER RES, V57, P1829
[5]  
Dorr RT, 1996, INVEST NEW DRUG, V14, P131
[6]   VINCA ALKALOIDS - ANTIVASCULAR EFFECTS IN A MURINE TUMOR [J].
HILL, SA ;
LONERGAN, SJ ;
DENEKAMP, J ;
CHAPLIN, DJ .
EUROPEAN JOURNAL OF CANCER, 1993, 29A (09) :1320-1324
[7]   ANTINEOPLASTIC AGENTS .145. ISOLATION AND STRUCTURE OF THE STRONG CELL-GROWTH AND TUBULIN INHIBITOR COMBRETASTATIN-A-4 [J].
PETTIT, GR ;
SINGH, SB ;
HAMEL, E ;
LIN, CM ;
ALBERTS, DS ;
GARCIAKENDALL, D .
EXPERIENTIA, 1989, 45 (02) :209-211
[8]   PHASE-I CLINICAL AND PHARMACOKINETIC STUDY OF ORAL ETOPOSIDE PHOSPHATE [J].
SESSA, C ;
ZUCCHETTI, M ;
CERNY, T ;
PAGANI, O ;
CAVALLI, F ;
DEFUSCO, M ;
DEJONG, J ;
GENTILI, D ;
MCDANIEL, C ;
PRINS, C ;
SCHACTER, I ;
WINOGRAD, B ;
DINCALCI, M .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (01) :200-209